Mark A. Robinson

Array ( [id] => 6185288 [patent_doc_number] => 20110124099 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-05-26 [patent_title] => 'IKKALPHA AND IKKBETA SPECIFIC INHIBITORS' [patent_app_type] => utility [patent_app_number] => 12/849359 [patent_app_country] => US [patent_app_date] => 2010-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 8198 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0124/20110124099.pdf [firstpage_image] =>[orig_patent_app_number] => 12849359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6475421 [patent_doc_number] => 20100284959 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-11-11 [patent_title] => 'SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 12/841506 [patent_app_country] => US [patent_app_date] => 2010-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 14823 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0284/20100284959.pdf [firstpage_image] =>[orig_patent_app_number] => 12841506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9503551 [patent_doc_number] => 08741865 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-06-03 [patent_title] => 'Treatment of immune disorders with Hom-1 inhibitors' [patent_app_type] => utility [patent_app_number] => 13/382641 [patent_app_country] => US [patent_app_date] => 2010-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 14145 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13382641 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8664440 [patent_doc_number] => 08377901 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-02-19 [patent_title] => 'Target host factors for treating viral infection' [patent_app_type] => utility [patent_app_number] => 12/831964 [patent_app_country] => US [patent_app_date] => 2010-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 26 [patent_no_of_words] => 21164 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12831964 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8452794 [patent_doc_number] => 20120263740 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-18 [patent_title] => 'APTAMER-TARGETED SIRNA TO INHIBIT NONSENSE MEDIATED DECAY' [patent_app_type] => utility [patent_app_number] => 13/380464 [patent_app_country] => US [patent_app_date] => 2010-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 36450 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13380464 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6433422 [patent_doc_number] => 20100278789 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-11-04 [patent_title] => 'METHODS OF GENERATING EXPANDED AND RE-DIFFERENTIATED ADULT ISLET BETA CELLS CAPABLE OF PRODUCING INSULIN' [patent_app_type] => utility [patent_app_number] => 12/817223 [patent_app_country] => US [patent_app_date] => 2010-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 24670 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0278/20100278789.pdf [firstpage_image] =>[orig_patent_app_number] => 12817223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9059642 [patent_doc_number] => 08546077 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-10-01 [patent_title] => 'Prostaglandin E2 modulation and uses thereof' [patent_app_type] => utility [patent_app_number] => 12/816820 [patent_app_country] => US [patent_app_date] => 2010-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 17 [patent_no_of_words] => 15588 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12816820 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8227807 [patent_doc_number] => 20120142011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-06-07 [patent_title] => 'Modified siNA' [patent_app_type] => utility [patent_app_number] => 13/378601 [patent_app_country] => US [patent_app_date] => 2010-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 9446 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13378601 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8197082 [patent_doc_number] => 20120121610 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-17 [patent_title] => 'THERAPEUTIC AGENT AND ASSAY' [patent_app_type] => utility [patent_app_number] => 13/376954 [patent_app_country] => US [patent_app_date] => 2010-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 19609 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0121/20120121610.pdf [firstpage_image] =>[orig_patent_app_number] => 13376954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8239927 [patent_doc_number] => 20120148664 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-06-14 [patent_title] => 'CHEMICAL MODIFICATIONS MOTIFS FOR MIRNA INHIBITORS AND MIMETICS' [patent_app_type] => utility [patent_app_number] => 13/377076 [patent_app_country] => US [patent_app_date] => 2010-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 7985 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13377076 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8228557 [patent_doc_number] => 20120142763 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-06-07 [patent_title] => 'NUCLEIC ACID DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 13/375451 [patent_app_country] => US [patent_app_date] => 2010-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 14662 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13375451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6149221 [patent_doc_number] => 20110020816 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-01-27 [patent_title] => 'Precursor miRNA loop-modulated target regulation' [patent_app_type] => utility [patent_app_number] => 12/802084 [patent_app_country] => US [patent_app_date] => 2010-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 60 [patent_figures_cnt] => 60 [patent_no_of_words] => 32028 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0020/20110020816.pdf [firstpage_image] =>[orig_patent_app_number] => 12802084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6110460 [patent_doc_number] => 20110189300 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-08-04 [patent_title] => 'siRNA SILENCING OF APOLIPOPROTEIN B' [patent_app_type] => utility [patent_app_number] => 12/784402 [patent_app_country] => US [patent_app_date] => 2010-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 221 [patent_figures_cnt] => 221 [patent_no_of_words] => 36439 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0189/20110189300.pdf [firstpage_image] =>[orig_patent_app_number] => 12784402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6292967 [patent_doc_number] => 20100239656 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-09-23 [patent_title] => 'EGFR/NEDD9/TGF-BETA INTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS' [patent_app_type] => utility [patent_app_number] => 12/777112 [patent_app_country] => US [patent_app_date] => 2010-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 50804 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0239/20100239656.pdf [firstpage_image] =>[orig_patent_app_number] => 12777112 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6202318 [patent_doc_number] => 20110065104 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-03-17 [patent_title] => 'REAL-TIME ASSAYS OF NEURO-HUMORAL FACTORS TO ASSESS CARDIOVASCULAR STRESS' [patent_app_type] => utility [patent_app_number] => 12/765607 [patent_app_country] => US [patent_app_date] => 2010-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 5844 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0065/20110065104.pdf [firstpage_image] =>[orig_patent_app_number] => 12765607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5944965 [patent_doc_number] => 20110105585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-05-05 [patent_title] => 'METHODS FOR DIAGNOSING AND TREATING SQUAMOUS CELL CARCINOMA UTILIZING miRNA-205 AND INHIBITORS THEREOF' [patent_app_type] => utility [patent_app_number] => 12/764674 [patent_app_country] => US [patent_app_date] => 2010-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 10422 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0105/20110105585.pdf [firstpage_image] =>[orig_patent_app_number] => 12764674 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6323804 [patent_doc_number] => 20100197012 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-08-05 [patent_title] => 'Application of RNA Interference Targeting dhfr Gene, to Cell for Producing Secretory Protein' [patent_app_type] => utility [patent_app_number] => 12/761193 [patent_app_country] => US [patent_app_date] => 2010-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 10533 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0197/20100197012.pdf [firstpage_image] =>[orig_patent_app_number] => 12761193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9273549 [patent_doc_number] => 08637481 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-01-28 [patent_title] => 'Sensitizing agents for cancer therapy, methods of use and methods for the identification thereof' [patent_app_type] => utility [patent_app_number] => 13/264598 [patent_app_country] => US [patent_app_date] => 2010-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 10482 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13264598 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7791673 [patent_doc_number] => 20120053229 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-03-01 [patent_title] => 'Regulation of MIR-33 MicroRNAs in the Treatment of Cholesterol-Related Disorders' [patent_app_type] => utility [patent_app_number] => 13/262083 [patent_app_country] => US [patent_app_date] => 2010-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 14565 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0053/20120053229.pdf [firstpage_image] =>[orig_patent_app_number] => 13262083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9153651 [patent_doc_number] => 08586557 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-11-19 [patent_title] => 'Therapy of p53 mutant colon adenocarcinoma, breast cancer and lung cancer' [patent_app_type] => utility [patent_app_number] => 12/731374 [patent_app_country] => US [patent_app_date] => 2010-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 19 [patent_no_of_words] => 13617 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12731374 [rel_patent_id] =>[rel_patent_doc_number] =>)